302 related articles for article (PubMed ID: 24157875)
1. APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase.
Peng X; Zhang MQ; Conserva F; Hosny G; Selivanova G; Bykov VJ; Arnér ES; Wiman KG
Cell Death Dis; 2013 Oct; 4(10):e881. PubMed ID: 24157875
[TBL] [Abstract][Full Text] [Related]
2. Rapid induction of cell death by selenium-compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine.
Anestål K; Arnér ES
J Biol Chem; 2003 May; 278(18):15966-72. PubMed ID: 12574159
[TBL] [Abstract][Full Text] [Related]
3. p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA.
Hedström E; Eriksson S; Zawacka-Pankau J; Arnér ES; Selivanova G
Cell Cycle; 2009 Nov; 8(21):3584-91. PubMed ID: 19838062
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246.
Haffo L; Lu J; Bykov VJN; Martin SS; Ren X; Coppo L; Wiman KG; Holmgren A
Sci Rep; 2018 Aug; 8(1):12671. PubMed ID: 30140002
[TBL] [Abstract][Full Text] [Related]
5. Plumbagin reduction by thioredoxin reductase 1 possesses synergy effects with GLUT1 inhibitor on KEAP1-mutant NSCLC cells.
Sun S; Zhang Y; Xu W; Yang R; Yang Y; Guo J; Ma Q; Ma K; Zhang J; Xu J
Biomed Pharmacother; 2022 Feb; 146():112546. PubMed ID: 34954641
[TBL] [Abstract][Full Text] [Related]
6. Ethaselen: a potent mammalian thioredoxin reductase 1 inhibitor and novel organoselenium anticancer agent.
Wang L; Yang Z; Fu J; Yin H; Xiong K; Tan Q; Jin H; Li J; Wang T; Tang W; Yin J; Cai G; Liu M; Kehr S; Becker K; Zeng H
Free Radic Biol Med; 2012 Mar; 52(5):898-908. PubMed ID: 22210352
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory nitrosylation of mammalian thioredoxin reductase 1: Molecular characterization and evidence for its functional role in cellular nitroso-redox imbalance.
Engelman R; Ziv T; Arnér ESJ; Benhar M
Free Radic Biol Med; 2016 Aug; 97():375-385. PubMed ID: 27377780
[TBL] [Abstract][Full Text] [Related]
8. Menadione inhibits thioredoxin reductase 1 via arylation at the Sec
Sun S; Xu W; Zhang Y; Yang Y; Ma Q; Xu J
Free Radic Biol Med; 2021 Aug; 172():482-489. PubMed ID: 34186208
[TBL] [Abstract][Full Text] [Related]
9. Details in the catalytic mechanism of mammalian thioredoxin reductase 1 revealed using point mutations and juglone-coupled enzyme activities.
Xu J; Cheng Q; Arnér ES
Free Radic Biol Med; 2016 May; 94():110-20. PubMed ID: 26898501
[TBL] [Abstract][Full Text] [Related]
10. Inhibition and crosslinking of the selenoprotein thioredoxin reductase-1 by p-benzoquinone.
Shu N; Cheng Q; Arnér ESJ; Davies MJ
Redox Biol; 2020 Jan; 28():101335. PubMed ID: 31590044
[TBL] [Abstract][Full Text] [Related]
11. A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death.
Ceder S; Eriksson SE; Cheteh EH; Dawar S; Corrales Benitez M; Bykov VJN; Fujihara KM; Grandin M; Li X; Ramm S; Behrenbruch C; Simpson KJ; Hollande F; Abrahmsen L; Clemons NJ; Wiman KG
EMBO Mol Med; 2021 Feb; 13(2):e10852. PubMed ID: 33314700
[TBL] [Abstract][Full Text] [Related]
12. Targeting Thioredoxin Reductase by Parthenolide Contributes to Inducing Apoptosis of HeLa Cells.
Duan D; Zhang J; Yao J; Liu Y; Fang J
J Biol Chem; 2016 May; 291(19):10021-31. PubMed ID: 27002142
[TBL] [Abstract][Full Text] [Related]
13. PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.
Zandi R; Selivanova G; Christensen CL; Gerds TA; Willumsen BM; Poulsen HS
Clin Cancer Res; 2011 May; 17(9):2830-41. PubMed ID: 21415220
[TBL] [Abstract][Full Text] [Related]
14. Oxidation of structural cysteine residues in thioredoxin 1 by aromatic arsenicals enhances cancer cell cytotoxicity caused by the inhibition of thioredoxin reductase 1.
Zhang X; Lu J; Ren X; Du Y; Zheng Y; Ioannou PV; Holmgren A
Free Radic Biol Med; 2015 Dec; 89():192-200. PubMed ID: 26169724
[TBL] [Abstract][Full Text] [Related]
15. APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells.
Mohell N; Alfredsson J; Fransson Å; Uustalu M; Byström S; Gullbo J; Hallberg A; Bykov VJ; Björklund U; Wiman KG
Cell Death Dis; 2015 Jun; 6(6):e1794. PubMed ID: 26086967
[TBL] [Abstract][Full Text] [Related]
16. Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy.
Bykov VJ; Zhang Q; Zhang M; Ceder S; Abrahmsen L; Wiman KG
Front Oncol; 2016; 6():21. PubMed ID: 26870698
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of mammalian thioredoxin reductase by black tea and its constituents: implications for anticancer actions.
Du Y; Wu Y; Cao X; Cui W; Zhang H; Tian W; Ji M; Holmgren A; Zhong L
Biochimie; 2009 Mar; 91(3):434-44. PubMed ID: 19059456
[TBL] [Abstract][Full Text] [Related]
18. PARP-1 inhibitors sensitize HNSCC cells to APR-246 by inactivation of thioredoxin reductase 1 (TrxR1) and promotion of ROS accumulation.
Yin ZX; Hang W; Liu G; Wang YS; Shen XF; Sun QH; Li DD; Jian YP; Zhang YH; Quan CS; Zeng Q; Li YL; Zhao RX; Ding Q; Xu ZX
Oncotarget; 2018 Jan; 9(2):1885-1897. PubMed ID: 29416738
[TBL] [Abstract][Full Text] [Related]
19. Thioredoxin reductase 1 and NADPH directly protect protein tyrosine phosphatase 1B from inactivation during H
Dagnell M; Pace PE; Cheng Q; Frijhoff J; Östman A; Arnér ESJ; Hampton MB; Winterbourn CC
J Biol Chem; 2017 Sep; 292(35):14371-14380. PubMed ID: 28684416
[TBL] [Abstract][Full Text] [Related]
20. Thioredoxin Reductase Inhibition for Cancer Therapy.
Gencheva R; Arnér ESJ
Annu Rev Pharmacol Toxicol; 2022 Jan; 62():177-196. PubMed ID: 34449246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
